Literature DB >> 1996549

Ceftazidime-induced hemolysis in a patient with drug-dependent antibodies reactive by immune complex and drug adsorption mechanisms.

L A Chambers1, L M Donovan, M S Kruskall.   

Abstract

A 35-year-old woman developed acute intravascular hemolysis within five days of beginning a course of ceftazidime. The direct antiglobulin test became strongly positive with both anti-IgG and anticomplement. The serum contained an antibody that, in the presence of ceftazidime, sensitized unmodified reagent cells with IgG and complement (immune-complex type). The serum also agglutinated ceftazidime-pretreated cells at room temperature and 37 degrees C (drug-adsorption type). Retrospective testing disclosed that the drug adsorption antibody, which had been present before the current course of antibiotics, was not demonstrable during the hemolysis. The reactivity of the immune complex antibody, which developed by the second day of ceftazidime, paralleled the degree of hemolysis and the strength of the direct antiglobulin test. The authors believe that this patient had two separate ceftazidime-dependent antibodies and that the antibody reactive by immune complex mechanism mediated an episode of acute intravascular hemolysis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1996549     DOI: 10.1093/ajcp/95.3.393

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

1.  Severe drug-induced immune haemolytic anaemia due to ceftazidime.

Authors:  Fei Chen; Zhuying Zhan
Journal:  Blood Transfus       Date:  2014-03-19       Impact factor: 3.443

Review 2.  Cephalosporin utilisation review and evaluation.

Authors:  G M Misan; C Dollman; D R Shaw; N Burgess
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

3.  The acute infection-associated hemolytic anemia of childhood: immunofluorescent detection of microbial antigens altering the erythrocyte membrane.

Authors:  R C Seitz; G Buschermöhle; G Dubberke; R Herbrand; M Maiwald; H H Hellwege
Journal:  Ann Hematol       Date:  1993-10       Impact factor: 3.673

4.  Haemolytic anaemia in association with Escherichia coli O157 infection in two sisters.

Authors:  C M Pennings; R C Seitz; H Karch; H G Lenard
Journal:  Eur J Pediatr       Date:  1994-09       Impact factor: 3.183

Review 5.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

6.  Case Report: Haemolytic anaemia with ceftazidime use in a patient with cystic fibrosis.

Authors:  Jun Yong; Freddy Frost; Dilip Nazareth; Martin Walshaw
Journal:  F1000Res       Date:  2018-04-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.